BUKS BUTLER NATIONAL CORP
Price Chart
Executive Summary
CEO Christopher Reedy disclosed in an employee email that he is undergoing a new course of cancer treatment at the Mayo Clinic. While he remains CEO and actively engaged, the treatment may periodically require time away from the office, creating near-term management uncertainty for a micro-cap company heavily reliant on its CEO.
Actionable Insight
Monitor for any further disclosures on CEO health status or interim leadership arrangements. If Reedy takes extended leave without a named successor, the stock may reprice to reflect key-person risk. Look for any 8-K filing naming an interim CEO or clarifying succession plans.
Key Facts
- CEO Christopher J. Reedy disclosed a new course of medical treatment for cancer, following regular follow-ups since a 2019 diagnosis.
- Reedy will continue as CEO and remain engaged, but treatment may require periodic time away from the office.
- The Board and executive leadership team stated they will support ongoing operations and strategic initiatives during his treatment.
- No financial details, revenue impact, or succession plan were disclosed.
Financial Impact
No specific financial amounts disclosed; key-person risk to a $10-50M market cap OTC company
Risk Factors
- CEO health deterioration could lead to extended absence at a micro-cap with concentrated leadership
- Lack of disclosed succession plan creates uncertainty
- No financial or operational detail provided — market may read this as withholding material information
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000015847-26-000009 |
| Document: buks-exx991xemlofchristoph.htm | 0000015847-26-000009 |
| Document: 0000015847-26-000009-index-headers.html | 0000015847-26-000009 |
| Document: 0000015847-26-000009-index.html | 0000015847-26-000009 |
| Document: 0000015847-26-000009.txt | 0000015847-26-000009 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access